FANCD2 and Friedreich ataxia: First, when the cell proliferation/survival after AICAR treatments was evaluated via the MTT assay in transformed fibroblasts established from an FA patient with defective FANCD2, FANCD2−/− fibroblast (GM16633A) were found to be more sensitive to AICAR treatments when compared with normal fibroblasts (Fig. 4A).